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Lytic reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8, from
latency requires transcriptional transactivation by the viral protein RTA encoded by the ORF50 gene. Very
little is known about how RTA functions and the cellular factors that may be involved in its transactivation
function. Using the yeast two-hybrid system, we have identified a human cellular protein that can interact with
KSHV RTA. The cellular protein, referred to as the human hypothetical protein MGC2663 by GenBank, is
encoded by human chromosome 19. This protein is 554 amino acids (aa) in size and displays sequence
similarity with members of the Krueppel-associated box–zinc finger proteins (KRAB-ZFPs). MGC2663 ex-
pression could be detected in all primate cell lines tested, and its expression level was neither stimulated nor
inhibited by RTA. MGC2663 specifically synergizes with RTA to activate viral transcription, and overexpres-
sion of MGC2663 in the presence of RTA further enhances RTA transactivation of several viral promoters that
were identified as targets for RTA. Coimmunoprecipitation and pull-down assays further demonstrated that
MGC2663 interacts with RTA both in vivo and in vitro, and the N-terminal 273 aa of KSHV RTA and the
potential zinc finger domain of MGC2663 are required for their interaction. Our results indicate that this novel
human cellular protein, MGC2663, named K-RBP (KSHV RTA binding protein) due to its RTA binding
feature, specifically interacts with the KSHV RTA protein and functions as a cellular RTA cofactor to activate
viral gene expression. Though its normal cellular function needs to be further studied, K-RBP may play a
significant role in mediating RTA transactivation in vivo.
Kaposi’s sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8, was first discovered in AIDS-
associated Kaposi’s sarcoma (KS) tissue in 1994 (4). Since
then, KSHV DNA has been detected in all other forms of KS,
including classic, endemic, and posttransplantation KS, as well
as in all clinical stages of KS (5, 6, 24, 31). Moreover, detection
of KSHV in peripheral blood mononuclear cells of human
immunodeficiency virus (HIV)-infected individuals predicts
the subsequent development of KS lesions (41). KSHV is also
associated with two other neoplastic disorders, primary effu-
sion lymphoma, also termed body cavity-associated lymphoma,
and multicentric Castleman’s disease (3, 12, 35). Since KS cell
lines usually do not harbor viral DNA, several KSHV-infected
human B-cell lines were established from primary effusion
lymphomas for molecular studies (2, 28). Viral gene expression
is highly restricted in these cell lines, indicating that the cells
are latently infected. Certain inducing agents, such as n-bu-
tyrate and tetradecanoyl phorbol acetate (TPA), can induce
lytic replication of KSHV from latency (28, 42).
The entire genomic sequence of KSHV has been reported,
and the virus has been classified in the Gamma 2 herpesvirus
(Rhadinovirus) subfamily (29, 31). Members of this subfamily,
including herpesvirus saimiri and murine herpesvirus 68, share
a common genome structure in which the encoding region of a
central open reading frame (ORF) is flanked by multirepetitive
high-GC-content DNA (29). KSHV reading frames are as-
signed the same number as their homologous versions in her-
pesvirus saimiri. Those genes unique to KSHV are given the
prefix K (for KSHV) and numbered sequentially (25). Based
on expression kinetics, herpesvirus genes can be categorized
into four groups: latent, immediate-early (IE), early, and late
genes. Expression of IE genes does not require any viral pro-
tein synthesis and is induced immediately after reactivation.
The genes of this group usually encode regulatory proteins that
up- or down-regulate the expression of various viral and cel-
lular genes and therefore play a crucial role in the switch from
latent to lytic replication.
The closest known relative of KSHV in humans is Epstein-
Barr virus (EBV), whose mechanism of reactivation has been
studied extensively (10, 27, 43). In this model, reactivation
from latency is controlled by two IE genes, BZLF1 and
BRLF1, whose products, ZEBRA and RTA, respectively, are
transcription activators that augment expression of down-
stream viral target genes (14, 16, 21, 38). KSHV also has a
homolog of the EBV BRLF1 gene, which is the ORF50 gene.
Expression of KSHV ORF50 can be detected as early as 1 h
after induction of viral replication and in the presence of the
protein synthesis inhibitor cycloheximide (18, 26, 37, 45). The
ORF50 gene has been shown to be crucial for viral replication
and gene transcription (13, 18, 19, 23, 36). Due to its similarity
to the EBV gene, its gene product has been referred to as the
KSHV RTA. As a typical transcription activator, KSHV RTA
contains an N-terminal basic domain and a C-terminal acidic
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activation domain located from amino acid (aa) 527 to 634.
The activation domain consists of three partially overlapping
hydrophobic motifs which are homologous with the transcrip-
tional activation domains of many transcription factors found
in viruses, yeast, and mammalian cells (39). It has been re-
ported that RTA activates expression of early genes, late
genes, and polyadenylated nuclear (PAN) RNA. The affected
early genes include ORF57, K8, and the gene for virus-en-
coded interleukin 6. The late genes include the small viral
capsid antigen gene (also known as ORF65) (17, 19, 20, 32, 36,
39). An RTA-responsive element (RRE) that can potentially
form a palindrome has been identified on both the ORF57 and
K8 gene promoters (20, 39). RTA was also found to autoregu-
late its own expression through a mechanism in which Oct-1
binding plays an important role (8, 30). These observations
strongly suggest that RTA may interact directly or indirectly
with its target sequences to stimulate transcription and that it
serves as a molecular switch for KSHV reactivation. Indeed,
RTA was recently found to bind directly to sequences in the
PAN RNA promoter region (34) and the RRE palindromes in
ORF57 and K8 promoters (20).
It has also recently been reported that both CREB-binding
protein (CBP) and histone deacetylase (HDAC) regulate RTA
function (15), and it has been suggested that cellular proteins
are involved in RTA functions. Identification and character-
ization of these cellular cofactors for RTA would be important
for deciphering the mechanism involved in the latent-lytic tran-
sition during viral reactivation. We performed a yeast two-
hybrid screening for RTA binding proteins (RBPs) with an
EBV-transformed B-cell cDNA library using an RTA C-ter-
minal mutant ORF50c as bait. A single protein of unknown
function was found to interact with RTA consistently. This
protein is identical to a hypothetical cellular protein termed
MGC2663 (from GenBank clone MGC:2663). The identified
protein consists of 554 aa, and it appears to encode an N-
terminal Krueppel-associated box (KRAB) and a C-terminal
zinc finger domain. Overexpression of MGC2663 stimulated
RTA transactivation of various target viral promoters in dif-
ferent mammalian cells. Both in vivo and in vitro interaction
between RTA and MGC2663 were confirmed by coimmuno-
precipitation and pull-down assays. Moreover, this association
was found to be independent of the C-terminal activation do-
main of RTA but required the RTA N terminus and the
MGC2663 zinc finger domain. Our data strongly suggests that
this novel cellular protein, MGC2663, also referred to as K-
RBP (for KSHV RBP), may be an important cofactor involved
in KSHV RTA transactivation and viral reactivation.
MATERIALS AND METHODS
Plasmids. All PCR-generated plasmids and fusion protein expression plasmids
were sequenced to verify the cloned inserts and their reading frames. Plasmid
pGBK/ORF50c, which was used as bait for yeast two-hybrid screening, was
generated from an RTA clone, pcDNA-ORF50c, consisting of the N-terminal
671 aa of RTA followed by the K8.1 region from nucleotide (nt) 76433 to 76690
(encoding 86 aa). The pcDNA-ORF50c clone was generated to study the effect
of K8.1 sequence on RTA transactivation function; it was cloned from a potential
spliced product observed in a 3 rapid amplification of cDNA ends study of the
ORF50-K8-K8.1 region. This clone retains both RTA DNA binding and trans-
activation domains but is not active in transactivation (unpublished data). The
insert of this clone was released with NotI and then cloned into the NcoI/SmaI
sites of the pGBKT7 DNA-BD vector (Clontech, Palo Alto, Calif.). This insert
was fused downstream of the N-terminal 147-aa DNA binding domain (DNA
BD) of Gal4 to generate plasmid pGBK/ORF50c for yeast two-hybrid screening.
Plasmid pGBK/ORF50 contains the full-length 691-aa RTA coding region fused
to the Gal4 DNA BD. Another plasmid that was used in the study, pGBK/
ORF50AD2, has an RTA insert with a deletion of 101 aa at the C terminus. The
plasmids pGBK-53 and pGAD-T encode the Gal4 DNA BD/murine p53 and
Gal4 activation domain (AD)/simian virus 40 large T antigen, respectively. These
two clones are known to interact in a yeast two-hybrid assay and were used
together as a positive control or in combination with our Gal4 fusion constructs
as negative controls.
The pcDNA-MGC2663 mammalian expression clone was generated from the
clone pACT-clone7 that was selected from a pACT vector-based cDNA library.
The insert of pACT-clone7 was released with BamHI/BglII and inserted into the
XhoI/BamHI sites of the pcDNA3.1() vector (Invitrogen, Carlsbad, Calif.) to
generate pcDNA-MGC2663 or into the EcoRI/BglII sites of the pCMV-HA
vector (Clontech) to generate pHA-MGC2663. Another MGC2663 yeast expres-
sion clone, pGAD-clone7, was generated by releasing the same BamHI/BglII
insert from pACT-clone7 and inserting it into the NcoI/BamHI sites of the
pGADT7 AD vector (Clontech) following the coding sequence for the Gal4 AD
from aa 768 to 881. The His-tagged mammalian fusion expression clone
pcDNA4His-2663 was generated from pcDNA-MGC2663 by releasing the
BstUI/XhoI insert of pcDNA-MGC2663 and inserting it into the EcoRV/XhoI
sites of the pcDNA4HisMax vector (Invitrogen). The bacterial expression clone
pET-MGC2663 was also generated by ligating the BstUI/XhoI insert of pcDNA-
MGC2663 into the NheI/XhoI sites of the pET28a vector (Novagen, Madison,
Wis.). The deletion clones pcDNA-MGC2663/242 and pHA-MGC2663/242,
which encode only the N-terminal 242 aa of MGC2663, were obtained by insert-
ing the small XhoI/NdeI fragment of pACT-clone7 into the XhoI/EcoRV sites of
pcDNA3.1() and inserting the SfiI/NdeI fragment of pHA-MGC2663 into the
SfiI/XhoI sites of pCMV-HA, respectively. Plasmid pEGFP-MGC2663, which
expresses MGC2663-green fluorescent protein (GFP) fusion protein, was gen-
erated by inserting the MGC2663 XhoI/EcoRI fragment of pcDNA-MGC2663
into the corresponding sites of the pEGFP-N1 vector (Clontech).
Clones pcDNA-ORF50, which encodes the full-length RTA, and pCMV-
Tag50, which encodes the Flag tag-fused RTA, were described previously (9, 39).
Clone pGEX-RTA, which expresses the glutathione-S-transferase (GST)-RTA
fusion protein, was generated by inserting the NotI/EcoRI fragment that contains
the entire ORF50 coding region obtained from an ORF50 clone, pcDNA-
ORF50R, into the EcoRI/NotI sites of pGEX-5X-3 (Amersham Pharmacia,
Piscataway, N.J.). Clone pGEX-RTA/273, which expresses the GST-fused RTA
N-terminal 273 aa, was derived from pGEX-RTA. It was generated by digesting
pGEX-RTA with NcoI/NotI to eliminate the small fragment. Plasmid pcDNA-
ORF50/548, which encodes the N-terminal 548 aa of RTA, was generated from
pcDNA-ORF50 by digestion with KpnI to eliminate the 470-bp fragment.
Reporter plasmids p57Pluc1, pK8Pluc, pMIPPluc, and p50LPluc contain
PCR-cloned promoter regions of ORF57 (from nt 81556 to 82008), ORF K8
(from nt 73851 to 74849), ORF K6 (vMIP-I) (from nt 27783 to 27422), and
ORF50 (from nt 70011 to 71576), respectively. The promoter fragments were
inserted into the NcoI/SacI sites upstream of the luciferase reporter gene of the
pGL3-Basic vector (Promega, Madison, Wis.) as described earlier (9, 39). Plas-
mid pGL3-promoter, which was used as a control, was from Promega. Plasmid
pHIVLTR-luc contains the PCR-generated HIV long terminal repeat (LTR)
region upstream of the luciferase gene on the pGL3-Basic vector. Plasmid
pcDNA-Tat expresses the full-length HIV Tat protein.
Yeast two-hybrid selection. Plasmid pGBK/ORF50c was transformed into
Saccharomyces cerevisiae AH109, which contains three reporter genes, his3, ade2,
and lacZ, by the lithium acetate-mediated method (yeast protocols handbook;
Clontech). The expression of yeast reporter genes was under the control of three
completely heterologous upstream activation sites (UAS) and promoter ele-
ments—gal1, gal2, and mel1, respectively. A pACT-based EBV-transformed hu-
man B-cell cDNA library tagged with the Gal4 AD (Clontech) was then trans-
formed into a pGBK/ORF50c yeast transformant for two-hybrid screening. After
a 3- to 5-day incubation at 30°C, yeast colonies that grew on synthetic dropout
(SD) plates lacking Ade, His, Leu, and Trp were streaked at least twice into a
single colony on SD agar lacking Leu and Trp to allow clones that contained
more than one library plasmid to segregate and then tested on SD agar lacking
Ade, His, Leu, and Trp to verify the phenotype. Positive colonies were trans-
ferred to nitrocellulose filters, permeabilized on the filters by freezing-thawing,
and then assayed for -galactosidase (-Gal) activity. Positive blue colonies were
picked and grown in SD medium lacking Leu and Trp. Plasmid DNA was
isolated and transformed into Escherichia coli DH5 to recover the positive
library clones. These clones were analyzed by restriction enzyme digestion fol-
lowed by sequencing. To further exclude the possibility of false positives, these
initially positive clones were cotransformed with pGBK/ORF50c into yeast
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strains AH109 and Y187, which contain the lacZ reporter gene under control of
the gal1 UAS. Growth of AH109 cotransformants was examined on SD plates
lacking His. More than three independent -Gal assays were performed from the
liquid culture of Y187 cotransformants using o-nitrophenyl--D-galactopyrano-
side as a substrate (yeast protocols handbook; Clontech).
Northern blot analysis. Total cellular RNA was prepared with the RNeasy kit
(Qiagen, Valencia, Calif.). Twenty micrograms of RNA from each sample was
analyzed on a 1.2% formaldehyde-agarose gel and then transferred to a nitro-
cellulose membrane. Restriction enzyme-released inserts from pcDNA-
MGC2663 and pcDNA-ORF50 plasmid DNAs, as well as a PCR-generated
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) fragment, were 32P la-
beled and used as probes in Northern blotting. After hybridization and washing,
the hybridized bands were detected with a PhosphorImager (Molecular Dynam-
ics, Sunnyvale, Calif.).
Cell culture, transfection, and luciferase assays. CV-1, 3T3, and human 293
cells were grown in Dubecco’s modified Eagle medium (Gibco BRL, Rockville,
Md.) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin
at 37°C in 5% CO2. The cell lines BC-3 (EBV/KSHV) and BJAB (EBV/
KSHV) were cultured in RPMI 1640 medium (Gibco BRL) supplemented with
10% fetal bovine serum and penicillin-streptomycin. To induce lytic replication
of KSHV in BC-3 cells, TPA was added to complete RPMI 1640 medium at a
concentration of 30 ng/ml for 24 h before the cells were harvested.
CV-1, 3T3, and 293 cells were transfected with Lipofectamine (Gibco BRL) as
described previously (7). Transfections of BJAB cells were performed by mixing
107 cells with 5 to 15 g of plasmid DNA in 0.6 ml of complete RPMI 1640
medium and then electroporating the mixture at 250 V and 960 F using the
GenePulser (Bio-Rad, Hercules, Calif.). The transfected cells were harvested
48 h posttransfection, and luciferase activities were measured (Luciferase Assay
System; Promega) according to the manufacturer’s procedure. Each result was
obtained from an average of multiple transfections from at least three indepen-
dent experiments.
Expression and purification of recombinant proteins. E. coli BL21(DE3)
cultures harboring recombinant protein expression plasmids were induced with 1
mM IPTG (isopropyl--D-thiogalactopyranoside) for 3 h at 37°C. The CV-1 cells
transfected with pcDNA4His-2663 or the vector control were harvested 40 h
posttransfection. The bacteria or cell pellets were then resuspended in ice-cold
phosphate-buffered saline (150 mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4,
pH 7.3) and sonicated. The cleared lysates were either resolved by sodium
dodecyl sulfate (SDS)–10% polyacrylamide gel electrophoresis (PAGE) or pu-
rified by affinity chromatography. For affinity purification, glutathione-Sepharose
4B beads (Amersham Pharmacia) were used for the GST fusion proteins and
Ni-nitrilotriacetic acid (NTA) beads (Qiagen) were used for the His-tagged
fusion proteins. Western blot analysis was performed using a rabbit antiserum
raised against the His-tagged N-terminal 376 aa of RTA or mouse anti-polyhis-
tidine (Sigma, St. Louis, Mo.) as the primary antibody, followed by alkaline
phosphatase-conjugated goat anti-rabbit or anti-mouse antibody (Bio-Rad), re-
spectively, as the secondary antibody. Signals were detected by chemilumines-
cence using CDP-Star (Boehringer-Mannheim, Indianapolis, Ind.) as the sub-
strate.
Transcription-translation of proteins and in vitro binding assay. 35S-labeled
proteins were synthesized in vitro using the TNT quick coupled transcription-
translation system (Promega) according to the manufacturer’s procedures, using
pcDNA-MGC2663, pcDNA-MGC2663/242, pcDNA-ORF50, or pcDNA-
ORF50/548 as a template. Recombinant proteins immobilized on beads were
pretreated with 0.2 U of DNase I and 0.2 g of RNase A per l for 0.5 h at 25°C
in pretreating buffer (50 mM Tris-HCl [pH 8.0], 5 mM MgCl2, 2.5 mM CaCl2,
100 mM NaCl, 5% glycerol, 1 mM dithiothreitol) as described previously (22).
The beads were washed twice with binding buffer (20 mM Tris-Cl [pH 7.5], 100
mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 1 mM dithiothreitol) and resus-
pended in the same buffer before the labeled proteins were added, followed by
incubation for 1 h at 4°C. The beads were then washed four times in binding
buffer, heated in SDS gel loading buffer, and analyzed by SDS-PAGE. The gels
were exposed to a phosphorimaging screen for 2 to 3 days and then analyzed.
Coimmunoprecipitation. CV-1 cells were cotransfected with pcDNA-ORF50
and pHA-MGC2663. At 48 h posttransfection, the cells were lysed in ice-cold IP
buffer (1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, and 2.5 mM
phenylmethylsulfonyl fluoride in phosphate-buffered saline) and sonicated. After
centrifugation, the cell lysates were precleared with 5 l of preimmune rabbit
serum and 50 l of a 50% slurry of protein A-Sepharose beads (Amersham
Pharmacia). RTA protein was precipitated with 5 l of rabbit antiserum against
RTA and protein A beads. The beads were washed four times with IP buffer and
heated in sample buffer to be analyzed by SDS-PAGE. Western blot analysis was
performed using polyvinylidene difluoride membranes with anti-hemagglutinin
(HA) polyclonal antibody (Clontech) and alkaline phosphatase-conjugated goat
anti-rabbit antibody.
Immunofluorescence assay. The CV-1 cells grown on glass coverslips were
cotransfected with pEGFP-MGC2663 and pCMV-Tag50. At 48 h posttransfec-
tion, the cells were fixed and immunostained using mouse anti-Flag (Stratagene,
La Jolla, Calif.) at 1:5,000 dilution as the primary antibody, followed by cyanine
5 (Cy5)-conjugated donkey anti-mouse (Jackson ImmunoResearch, West Grove,
Pa.) at 1:100 dilution as the secondary antibody. Samples were examined under
a Bio-Rad MRC1024ES confocal laser-scanning microscope equipped with an
argon-krypton laser. Optical images of GFP fusion proteins and Cy5 (laser lines,
488 and 640 nm, respectively; emission filters, 520 and 690 nm, respectively), as
well as the corresponding phase-contrast images, were collected simultaneously
using the dual-channel display mode of the Bio-Rad LaserSharp imaging program.
Nucleotide sequence accession number. The GenBank accession number for
the KSHV sequences reported in this study is KSU75698.
RESULTS
Yeast two-hybrid library screening identified a cellular pro-
tein that interacts with KSHV RTA. Yeast two-hybrid systems
provide a sensitive method for detecting relatively weak and
transient protein-protein interactions. In the selection system,
we used RTA as our bait and fused it downstream of the DNA
BD of the yeast transcription factor Gal4. A second construct
expressing the AD of Gal4 fused to sequences from a cDNA
library is able to activate reporter gene expression under the
control of the Gal4-responsive UAS and therefore enables the
selection of positive colonies. This activation will occur if the
library-encoded protein can interact with the bait protein to
bring the DNA BD and AD of Gal4 into close physical prox-
imity to the promoter region. The full-length RTA functions as
a transcription activator and showed a strong autologous acti-
vation of reporter genes in the absence of the Gal4 AD when
it was fused to the Gal4 DNA BD (Table 1). Therefore, the
full-length RTA cannot be used as bait. To overcome this
problem, we used a C-terminal mutant of RTA, ORF50c,
which contains the N-terminal 671-aa segment (with a C-ter-
minal 20-aa deletion) of RTA fused to an 86-aa segment en-
coded by the downstream K8.1 gene. This clone was con-
structed from a spliced ORF50 mRNA that was previously
TABLE 1. Reporter gene expression by yeast transformantsa
Plasmid with Ga14
DNA BD
Plasmid with
Ga14 AD
LacZ
expression
in Y187b
His expression
in AH109c
pGBK/ORF50 pGAD-T control  
pGBK/ORF50c pGAD-T control  
pGBK/ORF50c pACT-clone7  
pGBK/ORF50c pGAD-clone7  
pGBK/ORF50AD2 pGAD-T control  
pGBK/ORF50AD2 pACT-clone7  
pGBK/ORF50AD2 pGAD-clone7  
pGBK-53 control pACT-clone7  
pGBK-53 control pGAD-clone7  
pGBK-53 control pGAD-T control  
a The indicated yeast strains were cotransformed with the indicated Ga14
DNA BD and Ga14 AD plasmids. Cotransformants were selected using nutrition
selection markers for the vectors. The phenotypes of the colonies were analyzed
by liquid -Gal assays (for yeast strain Y187) and by their growth on SD plates
lacking His (for yeast strain AH109).
b , intense color development within 1 h in the liquid -Gal assays (about
20- and 10-fold higher, respectively, than clones designated and);, clone
was unable to develop any color after incubation with ONPG for more than 24 h
in the liquid -Gal assays.
c , colonies appeared after 2 days of incubation at 30°C on SD plates
lacking His; , colonies appeared after 4 days; , no growth.
VOL. 75, 2001 CELLULAR PROTEIN SYNERGIZING WITH KSHV RTA PROTEIN 11963
 by on February 7, 2009 
jvi.asm.org
D
ow
nloaded from
 
used to study the trans-acting function of RTA and was found
to be inactive against its target ORF57 promoter (unpublished
data). The clone pGBK/ORF50c, when fused to the Gal4 DNA
BD, was found to be incapable of activating reporter gene
expression by itself (Table 1) and was thus used as bait to
screen a Gal4 AD fusion B-cell cDNA library.
Among 3.5  106 yeast transformants that were screened,
17 clones were capable of continuous efficient growth in high-
stringency double-selection SD medium. Of the 17 clones that
were selected, 7 expressed -Gal activities and gave a positive
blue color in a colony lift filter assay. The other 10 clones were
found to be false positive and did not express any -Gal upon
retesting. The seven clones were then further characterized by
restriction enzyme pattern and DNA sequence analyses and
were subdivided into three groups. The first group of three
clones contained cDNA inserts that encode a hypothetical
human protein, MGC2663; the second group of two clones
contained partial sequence of the human mitochondrial ge-
nome; the third group of two clones contained a cDNA insert
encoding the EBV nuclear protein BMRF2, but in the reverse
orientation. When the plasmids purified from these positive
clones were cotransformed with the bait plasmid into yeast to
verify their positive interactions with RTA, only the first group,
which contained MGC2663 inserts, gave positive results in
both growth selection and liquid culture -Gal assays in dif-
ferent yeast strains (Table 1). These results demonstrated that
the insert contained in the first group of clones encodes a
product that can interact with RTA. To further analyze this
interaction, one clone (clone 7) from the first group was fur-
ther characterized. In addition to the positive interaction be-
tween clone 7 and ORF50c, clone 7 also interacted with an
RTA deletion mutant, ORF50AD2, which retains the N-ter-
minal 589 aa. This RTA mutant was not active in transactiva-
tion but was still able to interact with clone 7 when both were
cotransformed into yeast cells. To further confirm the interac-
tion between the clone 7 gene product and RTA, the insert of
clone 7 was released from the library vector and then trans-
ferred to another Gal4 AD vector, pGADT7, which can ex-
press higher levels of the fusion protein. When pGAD-clone7
was cotransformed into yeast cells with the RTA constructs,
the same positive results were observed with both ORF50c and
ORF50AD2, while no interaction with the pGBK-53 negative
control was observed (Table 1).
Clone 7 encodes the putative human MGC2663 protein lo-
cated on chromosome 19. Sequence analysis showed that the
insert of clone 7 is 2,062 nt in length and contains a long ORF
which fuses to the Gal4 AD region of the vector at the N
terminus in the same reading frame. Comparison of the Gen-
Bank database with the clone 7 sequence revealed that the
ORF is the complete coding sequence of a hypothetical human
protein, MGC2663, named after clone MGC:2663 (GenBank
accession numbers, BC001791 for the nucleotide and AAH01791
for the protein). Further analysis of the MGC2663 gene re-
vealed that it is located on chromosome 19 and is encoded by
the human chromosome 19 clone CTC-543D15 (GenBank ac-
cession number AC008567). The function of MGC2663 is cur-
rently not known, and its amino acid coding sequence was
derived entirely from the sequence of its cDNA clone. Com-
parison between our cDNA sequence and the corresponding
genomic sequence showed that the MGC2663 protein is gen-
erated by multiple splicing. It is encoded by six spliced exons,
with five small exons at the N terminus and a large one at the
C terminus (Fig. 1A). Although the structure of MGC2663 is
not known, amino acid sequence analysis identified a KRAB at
the N terminus from aa 42 to 98 and a C-terminal zinc finger
domain, starting from aa 224 (Fig. 1B). Up to 11 well-con-
served C2H2-type zinc finger motifs can be found in the C-
terminal domain.
Northern blot analysis of MGC2663 transcription. To de-
termine the size of the MGC2663 transcript and the possible
effect of KSHV reactivation on its expression, Northern blot
analyses were performed using various mammalian cell lines.
Total RNA was extracted from BC-3, BJAB, 293, 3T3, and
CV-1 cells and analyzed with a 32P-labeled MGC2663 probe. A
band of approximately 3.0 kb was detected from all human
cells and CV-1 cells tested but not from 3T3 cells. Since our
cDNA insert sequence would predict only a 2.1-kb transcript,
the detecting of a 3.0-kb novel cellular transcript suggests that
the MGC2663 transcript contain an untranslated sequence of
about 0.9 kb at the 5 end. Interestingly, TPA treatment of
BC-3 cells, which stimulates RTA expression (Fig. 2B), did not
seem to enhance MGC2663 expression (Fig. 2A, lanes 1 and
2), suggesting that MGC2663 may not be induced upon lytic
KSHV replication. In the MGC2663-transfected cells, in addi-
tion to the 3.0-kb cellular MGC2663 transcript, a 2.3-kb tran-
script encoded by the MGC2663 expression clone was also
observed. The transcript of 2.3 kb was expected from the trans-
fected MGC2663 expression plasmid because of the presence
of an extra 200 bp of plasmid-encoded flanking sequences in
addition to the 2.1-kb MGC2663 insert.
MGC2663 synergizes with RTA to activate transcription.
Based on the observed interaction between MGC2663 and
FIG. 1. Schematic representations of MGC2663 (clone 7) splicing
pattern and its potential functional domains. (A) Putative genomic
organization and splicing pattern of the MGC2663 gene. The indicated
nucleotide numbers of the potential splicing sites reflect the numbers
that were assigned to the GenBank human chromosome 19 clone
CTC-543D15 (GenBank AC008567). Conserved splicing donor (GT)
and acceptor (AG) sites are found at the ends of each exon. (B)
Schematic representation of MGC2663 protein. The putative KRAB
and the zinc finger domain are indicated.
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RTA in the yeast cells, we predicted that MGC2663 may be
involved in RTA transactivation and may be required for op-
timal activation of those viral promoters that are regulated by
RTA. To study this possibility, we tested several viral promot-
ers, such as the ORF57, K8, K6 (which encodes a homolog of
macrophage inflammatory protein vMIP-I), and ORF50 pro-
moters, which have been previously shown to be activated in
vitro by RTA (8, 9, 17, 32, 36, 39), and examined their RTA
responsiveness in the absence or presence of overexpressed
MGC2663 in various cell lines. As expected, the ORF57 pro-
moter was strongly activated by RTA in all the cell types tested,
ranging from 27-fold in 3T3 cells to 165-fold in BJAB cells.
Lower levels of activation were observed for K8, MIP, and
ORF50 promoters. Cotransfection of an MGC2663-expressing
plasmid further enhanced RTA activation of these viral pro-
moters in all four cell lines tested, while overexpression of
MGC2663 by itself did not seem to have any effect on the
activities of the promoters (Fig. 3). The enhancement effect of
MGC2663 varied among different promoters in different cell
lines. In general, higher levels of activation of the promoters by
RTA alone resulted in lower levels of enhancement in the
presence of MGC2663, such as in the activation of the ORF57
promoter in BJAB cells (Fig. 3D). The highest level of synergy
between RTA and MGC2663 was observed with the K8 pro-
moter in all cell types tested. When an increasing amount of
MGC2663 was cotransfected into CV-1 cells with an equal
amount of RTA plasmid DNA, a parallel increase in the levels
of MGC2663 stimulation was observed on the ORF57 and
MIP promoters tested (Fig. 3E). The effect of MGC2663 on
RTA transactivation appears to be specific for RTA and for
the promoters that are responsive to RTA, and it was found to
have no effect on the HIV transactivator Tat. Cotransfection of
MGC2663 with Tat and the HIV LTR did not show any syn-
ergistic effect on Tat transactivation of the HIV promoter (Fig.
3E). Activity of minimal simian virus 40 promoter was not
affected by either MGC2663 alone or the RTA/MGC2663
combination, suggesting that MGC2663 has no detectable ef-
fect on basal transcription activities (Fig. 3E). Our transfection
studies suggest that MGC2663 synergizes with RTA and plays
an accessory role in enhancing RTA transactivation. To further
demonstrate that the RTA expression level was not altered in
the MGC2663-cotransfected CV-1 cells, Western blot analysis
using rabbit anti-RTA antibody was carried out, and similar
levels of RTA protein were detected in both RTA-transfected
FIG. 2. Northern blot analysis of the expression pattern of MGC2663 gene in various mammalian cell lines. (A) MGC2663 transcript was
detected in all human cells tested and in CV-1 cells. Total cellular RNAs were extracted from BC-3 cells (untreated [BC-3] or TPA treated for
24 h [BC-3/TPA]) and BJAB cells (transfected with vector control [BJAB] or pcDNA-MGC2663 [BJAB/MGC2663]), as well as transfected
(/MGC2663) or control 293 cells, 3T3 cells, and CV-1 cells. Northern blotting was performed using a 32P-labeled MGC2663-specific probe and
analyzed by a PhosphorImager after a 2-day exposure. The RNA sizes according to the molecular size markers are indicated. The same membrane
was then rehybridized with a 32P-labeled GAPDH probe to ensure similar amounts of RNA were loaded onto each lane. (B) Northern blot analysis
of the RTA RNA in BC-3 cells. The same membrane used for panel A was stripped and reprobed with a 32P-labeled ORF50 probe. A 3.6-kb RTA
band was detected in both control and TPA-stimulated BC-3 cells.
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and RTA/MGC2663-cotransfected cells (Fig. 3F). Therefore,
the enhanced RTA transactivation in the presence of
MGC2663 was not due to the stimulation of RTA expression at
the transcriptional or translational level.
In vitro binding assay of MGC2663 and RTA. In order to
further explore the direct association between MGC2663 and
RTA, in vitro GST pull-down assays were performed using a
35S-labeled in vitro-translated (IVT) MGC2663 product and a
FIG. 3. Enhancement of RTA transactivation of various KSHV promoters by MGC2663. (A) Transfection of CV-1 cells was carried out with
50 ng of viral promoter reporter construct and 250 ng of pcDNA-ORF50 (RTA) and/or 500 ng of pcDNA-MGC2663 (MGC2663) () as indicated.
The total DNA amount used in each transfection was normalized by adding pcDNA3.1() vector. Luciferase activities were measured 48 h
posttransfection. The error bars indicate standard deviations. (B and C) Transfections of 3T3 and 293 cells were carried out as described for panel
A, using the same amounts of DNA for transfection. (D) Transfection of BJAB cells. In each transfection, 107 BJAB cells were mixed with 2 g
of reporter plasmid, 5 g of RTA expression plasmid, and/or 5 g of MGC2663 expression plasmid. Transfection was carried out using
electroporation as described in Materials and Methods. (E) MGC2663 stimulation of RTA activation is dose dependent and is specific for RTA
and its target promoters. CV-1 cells were transfected with 50 ng of KSHV promoter reporter construct, pGL3-promoter, or pHIVLTR-luc, as well
as the indicated amount of pcDNA-ORF50, pcDNA-Tat, and/or pcDNA-MGC2663. Each result represents an average of at least three
independent experiments. The standard deviations are shown as error bars. Transfection efficiency for each experiment was normalized using a
-Gal expression plasmid as an internal control. Fold activation was calculated based on the transfection of the reporter plasmid and the vector
control, which was normalized to 1. (F) Western blot analysis of RTA expression in transfected CV-1 cells in the presence or absence of MGC2663.
Lysates of cells transfected with either pcDNA-ORF50 alone (lane 1) or pcDNA-ORF50 and pcDNA-MGC2663 (lane 2) were analyzed using RTA
antiserum. The protein molecular mass markers are indicated.
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recombinant GST-fused RTA protein. The GST-RTA fusion
protein was first expressed in bacteria. A protein of about 95
kDa was detected by SDS-PAGE (Fig. 4A) and was confirmed
by Western blot analysis using RTA antiserum (Fig. 4B). To
study interaction between MGC2663 and RTA, the recombi-
nant GST-RTA was immobilized on glutathione-Sepharose 4B
beads, and 35S-labeled MGC2663 was allowed to bind to the
GST-RTA. The IVT MGC2663 was found to bind strongly in
the presence of GST-RTA, while only a very small amount of
IVT MGC2663 was found to bind nonspecifically (Fig. 4C). To
confirm that MGC2663 and RTA interact specifically, the re-
verse pull-down assay was carried out using the recombinant
MGC2663 protein to pull down IVT RTA. The recombinant
MGC2663 was expressed either in mammalian cells or in bac-
teria as a His-tagged fusion protein. The protein was expressed
at a higher level in bacteria, which can be detected by SDS-
PAGE and confirmed by Western blot analysis (Fig. 5A),
whereas in CV-1 cells the MGC2663 was expressed at a much
lower level, and the expressed protein could only be detected
by Western blotting (Fig. 5A). Both the mammalian-cell- and
bacterial-cell-expressed His-tagged MGC2663 proteins, after
being immobilized on Ni-NTA beads, were found to be capa-
ble of binding IVT RTA (Fig. 5B). Only a very small amount
of IVT RTA was found to bind nonspecifically to the NTA
beads in the absence of MGC2663. The level of this nonspecific
binding was highly variable, depending on the amount of la-
beled protein added, and was consistently weaker than the
specific signals in the presence of MGC2663. These results are
consistent with those of the GST pull-down assay (Fig. 4) and
further demonstrate that RTA and MGC2663 interact directly.
Coimmunoprecipitation of RTA and MGC2663. The syner-
gistic effect of MGC2663 on RTA transactivation and the bind-
ing of MGC2663 with RTA in vitro suggest that an in vivo
protein-protein interaction between RTA and MGC2663
should also occur. To confirm this possibility, a coimmunopre-
cipitation assay in transfected CV-1 cells was carried out (Fig.
6). CV-1 cells were cotransfected with RTA and HA-tagged
MGC2663 expression plasmids, and the expression of HA-
tagged MGC2663 in the transfected cell lysates was first con-
firmed by Western blot analysis (lane 1). Immunoprecipitation
of RTA from the cell lysates was then carried out using anti-
RTA rabbit serum. Precipitation of RTA by antiserum led to
the coprecipitation of MGC2663, which was detected by West-
ern blotting with anti-HA tag antibody (lane 2). In control cells
that were transfected with HA-tagged MGC2663 alone, RTA
antiserum was unable to precipitate MGC2663 in the absence
of RTA (lane 3). This result indicates that MGC2663 indeed
binds to RTA in vivo.
MGC2663 binds to the N terminus of RTA. To further char-
acterize the interaction between MGC2663 and RTA, an RTA
AD deletion clone, pcDNA-ORF50/548, was studied (Fig. 7A).
This clone contains the N-terminal 548 aa of RTA, and almost
the entire AD from aa 527 to 634 was deleted. The RTA/548
deletion mutant lost its transactivation function; it was not able
to activate either the ORF57 promoter- or the K8 promoter-
luciferase construct in CV-1 cells (Fig. 7B). To determine if
RTA with the deletion can still interact with MGC2663, the
RTA/548 clone was then translated in vitro and used in the His
tag pull-down assay as described earlier. Even though the de-
letion of the AD in RTA abolished its ability to transactivate
(Fig. 7B), this did not affect its ability to bind MGC2663. IVT
RTA/548 protein was able to interact with either the CV-1-
expressed or bacterially expressed His-tagged MGC2663 pro-
FIG. 4. Pull-down assays indicating that MGC2663 binds to GST-fused RTA in vitro. (A) Coomassie blue-stained gel of glutathione-Sepharose
4B bead-purified GST-fused RTA used in GST pull-down assay. (B) Western blot analysis of the GST-RTA using RTA antiserum to confirm the
expression of GST-fused RTA. (C) GST-fused RTA protein binds to IVT MGC2663 protein. In vitro-transcribed and -translated 35S-labeled
MGC2663 was added to either the immobilized GST-RTA or GST control. A control lane indicates the size of the labeled IVT MGC2663 using
input counts per minute about 20% of that used in the pull-down assay with GST-RTA. The protein molecular mass markers are indicated on the
side of each panel.
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tein (Fig. 7C), and the levels of binding were comparable to
those of the intact RTA protein (Fig. 5B).
In our previous study, another RTA deletion clone which
contains only the first 273 aa was found to have lost its trans-
activation activity (39), and we were interested in determining
if it could still interact with MGC2663. Therefore, to further
map the domain of RTA that may be involved in the interac-
tion with MGC2663, a second RTA deletion clone that con-
tained only the N-terminal 273-aa putative RTA DNA BD was
constructed. This clone, pGEX-RTA/273, was expressed as a
GST fusion protein. To determine whether this RTA deletion
mutant binds to MGC2663, it was expressed in bacteria and
used in the pull-down assay with IVT MGC2663. The RTA
N-terminal 273-aa GST fusion protein was well expressed in
bacteria and could be detected by SDS-PAGE at the expected
size and confirmed by Western blotting (Fig. 7D and E). The
amount of protein expressed was comparable to that of the
full-length GST-RTA fusion protein. When GST-RTA/273
was immobilized on glutathione beads, it was able to pull down
IVT MGC2663 but seemed to be binding less efficiently: less
MGC2663 appeared to bind to GST-RTA/273 than to the
intact RTA (Fig. 7F). These results indicate that the AD of
KSHV RTA is dispensable for association with MGC2663
while the N-terminal 273 aa confers its ability to bind.
The zinc finger domain of MGC2663 is required for associ-
ation with RTA. To investigate the domain of the MGC2663
protein that may be involved in the interaction with RTA, we
constructed an MGC2663 deletion mutant, MGC2663/242,
that retains the N-terminal 242 aa, including the entire KRAB,
but with most of the C-terminal zinc-finger domain deleted
(Fig. 8A). When the MGC2663 deletion clone was cotrans-
fected into CV-1 cells with RTA and either the ORF57 or K8
promoter, it was unable to synergize with RTA in transactiva-
FIG. 5. Pull-down assays indicating that RTA binds to His-tagged MGC2663 in vitro. (A) Western blot analysis of the His-tagged MGC2663
used in the pull-down assay, expressed either in CV-1 cells or in E. coli. The Western blotting was carried out using antibody against His tag. The
arrowhead indicates the expressed His-tagged MGC2663. (B) His-tagged MGC2663 protein binds to RTA. In vitro-transcribed and -translated
35S-labeled RTA was added to immobilized His-tagged MGC2663 that was expressed either in CV-1 cells or in E. coli. NTA beads were used as
a control for the pull-down assay. A control lane indicates the size of the labeled IVT RTA using input counts per minute about 20% of that used
in the pull-down assay with His-tagged MGC2663. The positions of protein markers are indicated.
FIG. 6. Immunoprecipitation of transfected CV-1 cells to demon-
strate that MGC2663 associates with RTA in vivo. CV-1 cells were
cotransfected with pcDNA-ORF50 and pHA-MGC2663 (lanes 1 and
2) or with pHA-MGC2663 alone (lane 3). The cell lysates were pre-
cipitated with RTA antiserum (lanes 2 and 3), and the coimmunopre-
cipitation of MGC2663 was detected using anti-HA antibody. Expres-
sion of HA-tagged MGC2663 in the total lysates was also indicated in
the same Western blot as a control (lane 1).
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tion of these viral promoters (Fig. 8B). To eliminate the pos-
sibility that the inability of MGC2663/242 to synergize with
RTA is due to problems with expression and stability of the
truncated protein, Western blot analysis using the transfected
cell lysates was carried out, using anti-HA antibody to detect
the expression of the HA-MGC2663/242 fusion protein (Fig.
8C). As expected, the approximately 28-kDa truncated HA-
MGC2663/242 was detected in the transfected cells, suggesting
that the protein was made but was unable to synergize with
RTA. These results indicate that the deleted region containing
the zinc finger domain of MGC2663 is necessary for the en-
hancement of RTA transactivation. We then further examined
the in vitro interaction between RTA and MGC2663/242, using
the immobilized GST-RTA and IVT MGC2663/242 in the
GST pull-down assay. As shown in Fig. 8D, neither GST-RTA
nor GST-RTA/273 pulled down the mutant protein MGC2663/
FIG. 7. The RTA N-terminal domain is responsible for interaction with MGC2663. (A) Schematic representations of RTA and the RTA AD
deletion clones. The basic region, AD, Leu zipper, and nuclear localizing signals (NLS) of RTA are indicated. The deletion clones RTA/548 and
GST-RTA/273, in which the C-terminal activation domain of RTA was deleted, are also shown. (B) The RTA/548 clone failed to activate both
ORF57 and K8 promoters in the transfection assays. CV-1 cells were transfected under the conditions described for Fig. 3A. Transfection was
carried out using 50 ng of reporter plasmid and 250 ng of pcDNA-ORF50 (RTA) or pcDNA-ORF50/548 (RTA/548). Fold activation was calculated
based on the transfection of the reporter plasmid and the vector control, which was normalized to 1. The error bars indicate standard deviations.
, present; , absent. (C) The RTA/548 protein retained its ability to bind to the His-tagged MGC2663. The His tag pull-down assay was
performed as described for Fig. 5B, using 35S-labeled IVT RTA/548. A control lane indicates the size of the labeled IVT RTA/548 using input
counts per minute about 20% of that used in the pull-down assay with His-tagged MGC2663. (D) The RTA deletion clone GST-RTA/273 was
expressed as a GST fusion protein and used in the pull-down assay with MGC2663. The Coomassie blue stain of the purified GST-RTA/273
indicates the correct deleted RTA protein was expressed. The intact GST-RTA protein was also purified and run on the same gel as a control. (E)
Western blot analysis using RTA antiserum to confirm that the GST-RTA/273 fusion protein of the correct size was expressed. The GST-RTA was
also run in parallel as a control. The arrowheads in panels D and E indicate the expressed proteins. (F) GST-RTA/273 retained its ability to bind
to MGC2663, but less MGC2663 protein seemed to bind than with the intact GST-RTA. The GST pull-down assay was performed as described
for Fig. 4C. A control lane indicates the size of the labeled IVT MGC2663 using input counts per minute about 20% of that used in the pull-down
assay with GST-RTA. The positions of protein markers are indicated.
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242 as they did the full-length MGC2663 (Fig. 7F), suggesting
that the failure of MGC2663/242 to stimulate RTA transacti-
vation is due to its inability to interact with RTA. Our results
demonstrate that the MGC2663 C-terminal zinc finger domain
is required for both interaction and synergy with RTA in tran-
scriptional activation.
MGC2663 colocalizes with RTA in vivo. Since MGC2663
may be involved in transcriptional regulation, it was important
to determine the subcellular localization of this protein and
whether the presence of RTA alters its localization. For this
purpose, a plasmid expressing the GFP-MGC2663 fusion pro-
tein was constructed and then transfected into CV-1 cells. The
transfected cells displayed fluorescence in the nucleus (Fig.
9A), suggesting that MGC2663 may be a nuclear protein. Since
RTA has been previously demonstrated to be a nuclear protein
(15), it was interesting to determine if RTA colocalizes in the
nucleus with MGC2663. The CV-1 cells were cotransfected
with pEGFP-MGC2663 and pCMV-Tag50, and the RTA pro-
tein was detected by immunofluorescence assay using mouse
anti-Flag antibody followed by Cy5-conjugated anti-mouse an-
tibody. The transfected RTA and MGC2663 were found to
colocalize in the nucleus, and the presence of RTA did not
seem to alter the localization pattern of MGC2663 (Fig. 9B).
These results further support those of our pull-down assays
and indicate that RTA and MGC2663 colocalize in the nucleus
and can interact in vivo to transactivate viral gene expression.
DISCUSSION
In this study, we have demonstrated that a novel cellular
protein named MGC2663 can interact with the KSHV RTA
directly and enhance RTA transactivation of several viral pro-
moters. This protein has been named K-RBP due to its RTA
binding feature. The KSHV RTA protein is an interesting
protein which is a homolog of the EBV IE gene product RTA.
KSHV RTA has been shown to be necessary for the induction
of lytic viral replication and activates different early and late
viral genes (13, 18, 19, 23). Several target genes for RTA
activation have been identified; they include ORF57, PAN
RNA, K8, and TK. The RTA protein was found to up-regulate
its own gene expression (8). Several studies, including ours,
have mapped the RREs for several viral promoters (9, 20, 34,
39). We found a common 16-bp element for the ORF57 and
K8 promoters, but there seem to be no consensus RREs
among all of the other RTA-responsive promoters. At the
moment, very little is known about the mechanism of RTA
FIG. 8. Deletion of the zinc finger domain of MGC2663 abolishes
its binding to RTA. (A) Schematic representation of MGC2663/242
deletion clone that was expressed and tested for its ability to interact
with RTA. A schematic representation of MGC2663 is shown for
comparison. (B) Transfection of the MGC2663/242 deletion clone to
determine its ability to enhance RTA activation of the ORF57 and K8
promoters. CV-1 cells were transfected under the conditions described
for Fig. 3A. The plasmid pcDNA-MGC2663/242 was added and com-
pared to the intact MGC2663 clone pcDNA-MGC2663 in the trans-
fection studies as indicated. Fold activation was calculated based on
the transfection of the reporter plasmid and the vector control, which
was normalized to 1. The error bars indicate standard deviations. ,
present; , absent. (C) Western blot analysis for the expression of
MGC2663 and MGC2663/242 in transfected cells. CV-1 cells were
transfected with 500 ng of pHA-MGC2663 or pHA-MGC2663/242,
and the cell lysates were analyzed using anti-HA antibody. (D) Pull-
down assay using purified GST-RTA or RTA deletion GST-RTA/273
proteins, with 35S-labeled IVT MGC2663/242 deletion protein.
MGC2663/242 did not bind to either GST-RTA or GST-RTA/273.
The GST pull-down assay was performed under the conditions de-
scribed for Fig. 4C but using 35S-labeled IVT MGC2663/242. A control
lane indicates the size of the labeled IVT MGC2663/242 using input
counts per minute about 20% of that used in the pull-down assay with
GST-RTA. The positions of protein markers are indicated.
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transactivation, and it is possible that RTA can bind either
directly or indirectly to the elements located in the target
promoters to enhance transcription. It was reported recently
that RTA can bind directly to the PAN RNA promoter se-
quences (34), suggesting that RTA-DNA binding could be
involved in the transcriptional activation of PAN RNA expres-
sion. However, binding of RTA to the ORF57/K8 RRE seems
to be weaker than to the PAN RNA promoter (20, 34, 39), and
it is possible that RTA may be interacting with the RREs of
these other target genes via cellular factors. The K-RBP pro-
tein that is identified in the present study may be one of these
factors involved in the sequestering of RTA in the vicinity of
the RREs of both the K8 and ORF57 promoters to activate
gene expression. However, it is not clear at the moment wheth-
er K-RBP can directly and specifically interact with DNA, and
whether it can bind to the RRE in the ORF57 promoter needs
to be determined. Indeed, we have previously observed (un-
published data) that labeled K8 and ORF57 RRE probes con-
sistently complexed with a cellular protein(s) in a mobility shift
assay using either RTA-transfected or untransfected normal
cellular nuclear extracts; whether K-RBP is part of the DNA-
protein complex remains to be determined.
Cellular cofactors are often found to be involved in tran-
scriptional activation by viral transactivators. One of the best-
characterized viral transactivators is HIV Tat; it was shown to
interact with cellular factors such as cyclin and CDK9 (40). The
K-RBP protein that we have found is the first RTA-interacting
protein identified by the yeast two-hybrid screening using RTA
as bait. Since RTA itself is a potent transactivator giving high
levels of background transcriptional activities in the absence of
any other cellular cofactors, it cannot be used directly as bait;
therefore, a nonfunctional RTA clone had to be used in our
study. Interestingly, the cDNA expression library that we used
for screening with RTA was from an EBV-transformed lym-
phoma cell line, and only K-RBP was found to consistently
bind to RTA. This suggests that either there was no EBV-
encoded gene product that could interact with RTA or the
specific EBV gene was not represented in the lymphoma cell
cDNA library. In addition to the K-RBP that we have identi-
fied in this study, it was reported recently that the cellular
proteins CBP and HDAC can also interact with RTA, with
CBP activating and HDAC repressing RTA-mediated viral
transcription (15). Binding of CBP to RTA requires the C-
terminal activation domain of RTA, while HDAC binds to a
central proline-rich segment in RTA. With regard to other
cellular factors, it was found that RTA transactivation of
KSHV thymidine kinase promoter requires the SP-1 element,
suggesting SP-1 may be involved (44). However, it is unlikely
that SP-1 is involved with all RTA-responsive genes, because
the SP-1 site was not observed with either the ORF57 or the
K8 promoter that was found to be responsive to transactivation
(39).
We have found that K-RBP was expressed in different pri-
mate cells tested but not in mouse 3T3 cells, and a single
K-RBP RNA species of about 3.0 kb was detected. This sug-
gests that either the K-RBP gene is unique to primate cells or
the mouse homolog of this gene is so divergent from that of the
primates that it could not be detected by our human K-RBP
probe. Whether K-RBP is a member of a gene family and
whether similar genes can be found in other animal species
need to be further investigated. Based on the genomic se-
quence, the K-RBP mRNA is a spliced product with six exons
spanning a genomic fragment of over 8.3 kb. Interestingly,
based on Northern analysis, the K-RBP mRNA seems to have
a long 5 untranslated region of about 0.9 kb. The implications
for the presence of a long 5-untranslated region also need to
be further investigated.
FIG. 9. Colocalization of MGC2663 and RTA proteins in the nu-
clei of transfected cells. (A) Cellular localization of MGC2663. CV-1
cells grown on coverslips were transfected with pEGFP-MGC2663,
and the transfected cells were observed under a confocal microscope
48 h posttransfection. (B) MGC2663 colocalizes with RTA. CV-1 cells
cotransfected with the plasmids pEGFP-MGC2663 and pCMV-Tag50
were observed 48 h posttransfection. The top left panel represents the
localization of the GFP-MGC2663 observed using a 488- and 520-nm
filter to detect green fluorescence. The top right panel represents the
localization of Flag-RTA protein using mouse anti-Flag antibody fol-
lowed by Cy5-conjugated anti-mouse antibody. The 640- and 690-nm
filter was used to detect the red Cy5 staining. The lower left panel
represents the dual detection of both GFP-MGC2663 and Flag-RTA
proteins. Phase contrast represents the cells observed under bright
field.
VOL. 75, 2001 CELLULAR PROTEIN SYNERGIZING WITH KSHV RTA PROTEIN 11971
 by on February 7, 2009 
jvi.asm.org
D
ow
nloaded from
 
The K-RBP protein displays a typical structure of a member
of the KRAB-zinc finger protein (ZFP) family. It contains an
N-terminal KRAB domain and a C-terminal zinc-finger do-
main composed of 11 C2H2 motifs, which are commonly found
in most KRAB-ZFPs. Mammalian genomes are known to con-
tain a large number of KRAB-zinc finger genes, and many of
them encode 10 or more C2H2-type zinc finger motifs. Mem-
bers of this large gene family have diverged in both sequence
and expression patterns (33) and therefore may yield families
of proteins with distinct, yet related, functions. In contrast to
our findings here that K-RBP has no remarkable effect on
general transcription but acts as a cofactor for RTA to stimu-
late RTA-mediated viral gene transactivation, other KRAB-
containing ZFPs were found to repress both basal and VP16-
activated transcription when targeted to DNA in vitro (1). It
was proposed that members of the KRAB-ZFP family function
as transcription factors that bind DNA through the zinc finger
domain and repress gene expression via the KRAB domain
(11). In this study, we have demonstrated that the zinc finger
domain of K-RBP is involved in the interaction with RTA and
stimulates RTA-mediated transcription activation, but it is not
clear whether K-RBP and its zinc finger domain are also in-
volved in DNA binding. Our results nevertheless suggest that
human KRAB-ZFP-like K-RBP protein interacts with RTA
and stimulates RTA-mediated viral gene expression through a
mechanism that could be different from that involved in the
transcription repression by other KRAB-ZFP family members.
In this study, we have found that four different KSHV pro-
moters, those of ORF57, K8, MIP, and ORF50, regardless of
whether they are expressed early or late after viral infection,
were all further stimulated by K-RBP in the presence of RTA.
Among these viral promoters, only those of ORF57 and K8
share a common RRE. It is possible that RTA may not be
binding directly to the other two promoters but could be teth-
ered to these targets via common cellular factors, such as
K-RBP. The colocalization of both RTA and K-RBP in the
nucleus strongly supports the notion that they complex in vivo
to mediate transcriptional activation, but we could not deter-
mine whether it is RTA or yet another cellular factor that may
be tethering K-RBP to the viral promoter targets in the nu-
cleus. Our sequence analysis of K-RBP did not reveal any
typical nuclear localizing signal, but further analysis needs to
be carried out to determine how K-RBP can be targeted to the
nucleus. Even though K-RBP appears to be localized in the
nucleus, whether it plays a role in transcription regulation in
the absence of RTA is unclear. Further studies are also needed
in order to determine the role of K-RBP in KSHV lytic viral
replication and to decipher the mechanism involved in RTA-
mediated viral gene transcription.
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